Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'IMMUNODEFICIENCY-VIRUS PROTEASE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 190 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Rezacova, P; Lescar, J; Brynda, J; Fabry, M; Horejsi, M; Sedlacek, J; Bentley, GA
      Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody

      STRUCTURE
    2. Marastoni, M; Bazzaro, M; Salvadori, S; Bortolotti, F; Tomatis, R
      HIV-1 protease inhibitors containing an N-hydroxyamino acid core structure

      BIOORGANIC & MEDICINAL CHEMISTRY
    3. Matsumoto, H; Matsuda, T; Nakata, S; Mitoguchi, T; Kimura, T; Hayashi, Y; Kiso, Y
      Synthesis and biological evaluation of prodrug-type anti-HIV agents: Esterconjugates of carboxylic acid-containing dipeptide HIV protease inhibitorsand a reverse transcriptase inhibitor

      BIOORGANIC & MEDICINAL CHEMISTRY
    4. Wang, L; Duan, Y; Stouten, P; De Lucca, GV; Klabe, RM; Kollman, PA
      Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations

      JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    5. Melani, F; Gratteri, P; Adamo, M; Bonaccini, C
      FILO (Field Interaction Ligand Optimization): A simplex strategy for searching the optimal ligand interaction field in drug design

      JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    6. Pillai, B; Kannan, KK; Hosur, MV
      1.9 angstrom X-ray study shows closed flap conformation in crystals of tethered HIV-1PR

      PROTEINS-STRUCTURE FUNCTION AND GENETICS
    7. Israili, ZH; Dayton, PG
      Human alpha-1-glycoprotein and its interactions with drugs

      DRUG METABOLISM REVIEWS
    8. Buss, N; Snell, P; Bock, J; Hsu, A; Jorga, K
      Saquinavir and ritonavir pharmacokinetics following combined ritonavir andsaquinavir (soft gelatin capsules) administration

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    9. Jones, K; Hoggard, PG; Khoo, S; Maher, B; Back, DJ
      Effect of alpha(1)-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    10. Pellegrin, I; Breilh, D; Birac, V; Deneyrolles, M; Mercie, P; Trylesinski, A; Neau, D; Saux, MC; Fleury, HJA; Pellegrin, JL
      Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens

      THERAPEUTIC DRUG MONITORING
    11. Gill, J; Feinberg, J
      Saquinavir soft gelatin capsule - A comparative safety review

      DRUG SAFETY
    12. Chiba, M; Jin, LX; Neway, W; Vacca, JP; Tata, JR; Chapman, K; Lin, JH
      P450 interaction with HIV protease inhibitors: Relationship between metabolic stability, inhibitory potency, and p450 binding spectra

      DRUG METABOLISM AND DISPOSITION
    13. Thompson, LA; Tebben, AJ
      Chapter 24. Pharmacokinetics and design of aspartyl protease inhibitors

      ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 36
    14. Ghosh, AK; Bilcer, G; Schiltz, G
      Syntheses of FDA approved HIV protease inhihitors

      SYNTHESIS-STUTTGART
    15. Grub, S; Bryson, H; Goggin, T; Ludin, E; Jorga, K
      The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    16. Zucker, SD; Qin, XF; Rouster, SD; Yu, F; Green, RM; Keshavan, P; Feinberg, J; Sherman, KE
      Mechanism of indinavir-induced hyperbilirubinemia

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    17. Huisman, MT; Smit, JW; Wiltshire, HR; Hoetelmans, RMW; Beijnen, JH; Schinkel, AH
      P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir

      MOLECULAR PHARMACOLOGY
    18. Pyring, D; Lindberg, J; Rosenquist, A; Zuccarello, G; Kvarnstrom, I; Zhang, H; Vrang, L; Unge, T; Classon, B; Hallberg, A; Samuelsson, B
      Design and synthesis of potent C-2-symmetric diol-based HIV-1 protease inhibitors: Effects of fluoro substitution

      JOURNAL OF MEDICINAL CHEMISTRY
    19. Kuhelj, R; Rizzo, CJ; Chang, CH; Jadhav, PK; Towler, EM; Korant, BD
      Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays

      JOURNAL OF BIOLOGICAL CHEMISTRY
    20. Trylska, J; Grochowski, P; Geller, M
      Parameterization of the approximate valence bond (AVB) method to describe potential energy surface in the reaction catalyzed by HIV-1 protease

      INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
    21. Panchal, SC; Bhavesh, NS; Hosur, RV
      Real time NMR monitoring of local unfolding of HIV-1 protease tethered dimer driven by autolysis

      FEBS LETTERS
    22. Tayrouz, Y; Ganssmann, B; Ding, R; Klingmann, A; Aderjan, R; Burhenne, J; Haefeli, WE; Mikus, G
      Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    23. Verkhivker, GM; Rejto, PA; Bouzida, D; Arthurs, S; Colson, AB; Freer, ST; Gehlhaar, DK; Larson, V; Luty, BA; Marrone, T; Rose, PW
      Parallel simulated tempering dynamics of ligand-protein binding with ensembles of protein conformations

      CHEMICAL PHYSICS LETTERS
    24. Ma, C; Nakamura, N; Hattori, M
      Inhibitory effects on HIV-1 protease of tri-p-coumaroylspermidine from Artemisia caruifolia and related amides

      CHEMICAL & PHARMACEUTICAL BULLETIN
    25. Northrop, DB
      Follow the protons: A low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases

      ACCOUNTS OF CHEMICAL RESEARCH
    26. Mallolas, J; Blanco, JL; Sarasa, M; Giner, V; Martinez, E; Garcia-Viejo, MA; Arnaiz, JA; Cruceta, A; Soy, D; Tuset, M; Soriano, A; Codina, C; Pumarola, T; Carne, X; Gatell, JM
      Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    27. Aymard, G; Legrand, M; Trichereau, N; Diquet, B
      Determination of twelve antiretroviral agents in human plasma sample usingreversed-phase high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    28. Strisovsky, K; Tessmer, U; Langner, J; Konvalinka, J; Krausslich, HG
      Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: Rethinking the "fireman's grip" hypothesis

      PROTEIN SCIENCE
    29. Collinsova, M; Jiracek, J
      Phosphinic acid compounds in biochemistry, biology and medicine

      CURRENT MEDICINAL CHEMISTRY
    30. Jalaie, M; Erickson, JA
      Homology model directed alignment selection for comparative molecular field analysis: Application to photosystem II inhibitors

      JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    31. Shiraki, N; Hamada, A; Yasuda, K; Fujii, J; Arimori, K; Nakano, M
      Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    32. Munshi, S; Chen, ZG; Yan, YW; Li, Y; Olsen, DB; Schock, HB; Galvin, BB; Dorsey, B; Kuo, LC
      An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease

      ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
    33. Fletcher, CV; Acosta, EP; Cheng, HL; Haubrich, R; Fischl, M; Raasch, R; Mills, C; Hu, XJ; Katzenstein, D; Remmel, RP; Gulick, RM
      Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884

      AIDS
    34. Murphy, RL
      New antiretroviral drugs in development

      AIDS
    35. Newman, DJ; Cragg, GM; Snader, KM
      The influence of natural products upon drug discovery

      NATURAL PRODUCT REPORTS
    36. Won, Y
      Binding free energy simulations of the HIV-1 protease and hydroxyethylene isostere inhibitors

      BULLETIN OF THE KOREAN CHEMICAL SOCIETY
    37. Wlodawer, A; Gustchina, A
      Structural and biochemical studies of retroviral proteases

      BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY
    38. Zheng, WF; Tropsha, A
      Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle

      JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES
    39. Brophy, DF; Israel, DS; Pastor, A; Gillotin, C; Chittick, GE; Symonds, WT; Lou, Y; Sadler, BM; Polk, RE
      Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    40. Shibata, N; Matsumura, Y; Okamoto, H; Kawaguchi, Y; Ohtani, A; Yoshikawa, Y; Takada, K
      Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors

      JOURNAL OF PHARMACY AND PHARMACOLOGY
    41. Wang, W; Kollman, PA
      Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model

      JOURNAL OF MOLECULAR BIOLOGY
    42. Figueiredo, LJO; Antunes, OAC
      Chemometric classification of HIV-1 protease inhibitors

      INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
    43. Noble, S; Goa, KL
      Amprenavir - A review of its clinical potential in patients with HIV infection

      DRUGS
    44. Park, H; Suh, J; Lee, S
      Ab initio studies on the catalytic mechanism of aspartic proteinases: Nucleophilic versus general acid/general base mechanism

      JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    45. Langmann, P; Klinker, H; Schirmer, D; Zilly, M; Bienert, A; Richter, E
      High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir inplasma of patients during highly active antiretroviral therapy

      JOURNAL OF CHROMATOGRAPHY B
    46. Rose, MJ; Merschman, SA; Woolf, EJ; Matuszewski, BK
      Determination of L-756 423, a novel HIV protease inhibitor, in human plasma and urine using high-performance liquid chromatography with fluorescence detection

      JOURNAL OF CHROMATOGRAPHY B
    47. Louis, JM; Clore, GM; Gronenborn, AM
      Autoprocessing of HIV-1 protease is tightly coupled to protein folding

      NATURE STRUCTURAL BIOLOGY
    48. Pai, VB; Nahata, MC
      Nelfinavir mesylate: A protease inhibitor

      ANNALS OF PHARMACOTHERAPY
    49. Ishima, R; Freedberg, DI; Wang, YX; Louis, JM; Torchia, DA
      Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function

      STRUCTURE WITH FOLDING & DESIGN
    50. Xie, D; Gulnik, S; Gustchina, E; Yu, B; Shao, W; Qoronfleh, W; Nathan, A; Erickson, JW
      Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH

      PROTEIN SCIENCE
    51. Trylska, J; Antosiewicz, J; Geller, M; Hodge, CN; Klabe, RM; Head, MS; Gilson, MK
      Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease

      PROTEIN SCIENCE
    52. Gatanaga, H; Aizawa, S; Kikuchi, Y; Tachikawa, N; Genka, I; Yoshizawa, S; Yamamoto, Y; Yasuoka, A; Oka, S
      Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    53. Greenblatt, DJ; von Moltke, LL; Daily, JP; Harmatz, JS; Shader, RI
      Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    54. van Heeswijk, RPG; Veldkamp, AI; Hoetelmans, RMW; Mulder, JW; Schreij, G; Hsu, A; Lange, JMA; Beijnen, JH; Meenhorst, PL
      The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

      AIDS
    55. Lin, JH
      Role of pharmacokinetics in the discovery and development of indinavir

      ADVANCED DRUG DELIVERY REVIEWS
    56. Aungst, BJ
      P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs

      ADVANCED DRUG DELIVERY REVIEWS
    57. Humphrey, RW; Wyvill, KM; Nguyen, BY; Shay, LE; Kohler, DR; Steinberg, SM; Ueno, T; Fukasawa, T; Shintani, M; Hayashi, H; Mitsuya, H; Yarchoan, R
      A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

      ANTIVIRAL RESEARCH
    58. Yamaji, H; Matsumura, Y; Yoshikawa, Y; Takada, K
      Pharmacokinetic interactions between HIV-protease inhibitors in rats

      BIOPHARMACEUTICS & DRUG DISPOSITION
    59. Popov, ME; Kashparov, IV; Rumsh, LD; Popov, EM
      Mechanism of action of aspartyl proteases. VII. Noncovalent complexes of HIV-1 aspartic protease with substrate and substrate-like inhibitor

      BIOORGANICHESKAYA KHIMIYA
    60. Davit, B; Reynolds, K; Yuan, R; Ajayi, F; Conner, D; Fadiran, E; Gillespie, B; Sahajwalla, C; Huang, SM; Lesko, LJ
      FDA evaluations using in vitro metabolism to predict and interpret in vivometabolic drug-drug interactions: Impact on labeling

      JOURNAL OF CLINICAL PHARMACOLOGY
    61. Huang, SM; Lesko, LJ; Williams, RL
      Assessment of the quality and quantity of drug-drug interaction studies inrecent NDA submissions: Study design and data analysis issues

      JOURNAL OF CLINICAL PHARMACOLOGY
    62. Kumar, GN; Dykstra, J; Roberts, EM; Jayanti, VK; Hickman, D; Uchic, J; Yao, Y; Surber, B; Thomas, S; Granneman, GR
      Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

      DRUG METABOLISM AND DISPOSITION
    63. Kumar, GN; Jayanti, V; Lee, RD; Whittern, DN; Uchic, J; Thomas, S; Johnson, P; Grabowski, B; Sham, H; Betebenner, D; Kempf, DJ; Denissen, JF
      In vitro metabolism of the HIV-1 protease inhibitor ABT-378: Species comparison and metabolite identification

      DRUG METABOLISM AND DISPOSITION
    64. Aguilar, N; Moyano, A; Pericas, MA; Riera, A
      A convergent, stereocontrolled synthesis of C-2-symmetrical and pseudosymmetrical sulfur-tethered bis(amino alcohols)

      TETRAHEDRON LETTERS
    65. Gutmann, H; Fricker, G; Drewe, J; Toeroek, M; Miller, DS
      Interactions of HIV protease inhibitors with ATP-dependent drug export proteins

      MOLECULAR PHARMACOLOGY
    66. Yeh, KC; Stone, JA; Carides, AD; Rolan, P; Woolf, E; Ju, WD
      Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique:Study design and model-independent data analysis

      JOURNAL OF PHARMACEUTICAL SCIENCES
    67. Klopman, G; Tu, M
      Diversity analysis of 14 156 molecules tested by the National Cancer Institute for anti-HIV activity using the quantitative structure-activity relational expert system MCASE

      JOURNAL OF MEDICINAL CHEMISTRY
    68. Hulten, J; Andersson, HO; Schaal, W; Danielson, HU; Classon, B; Kvarnstrom, I; Karlen, A; Unge, T; Samuelsson, B; Hallberg, A
      Inhibitors of the C-2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2 ' side chains

      JOURNAL OF MEDICINAL CHEMISTRY
    69. De Lucca, GV; Liang, J; De Lucca, I
      Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors

      JOURNAL OF MEDICINAL CHEMISTRY
    70. Berry, C; Humphreys, MJ; Matharu, P; Granger, R; Horrocks, P; Moon, RP; Certa, U; Ridley, RG; Bur, D; Kay, J
      A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum

      FEBS LETTERS
    71. Mahalingam, B; Louis, JM; Reed, CC; Adomat, JM; Krouse, J; Wang, YF; Harrison, RW; Weber, IT
      Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

      EUROPEAN JOURNAL OF BIOCHEMISTRY
    72. Michelet, C; Bellissant, E; Ruffault, A; Arvieux, C; Delfraissy, JF; Raffi, F; Bazin, C; Renard, I; Sebille, V; Chauvin, JP; Dohin, E; Cartier, F
      Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    73. Garg, R; Gupta, SP; Gao, H; Babu, MS; Debnath, AK; Hansch, C
      Comparative quantitative structure-activity relationship studies on anti-HIV drugs

      CHEMICAL REVIEWS
    74. Martin, JL; Begun, J; Schindeler, A; Wickramasinghe, WA; Alewood, D; Alewood, PF; Bergman, DA; Brinkworth, RI; Abbenante, G; March, DR; Reid, RC; Fairlie, DP
      Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease

      BIOCHEMISTRY
    75. Drewe, J; Gutmann, H; Fricker, G; Torok, M; Beglinger, C; Huwyler, J
      HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833

      BIOCHEMICAL PHARMACOLOGY
    76. Short, GF; Lodder, M; Laikhter, AL; Arslan, T; Hecht, SM
      Caged HIV-1 protease: Dimerization is independent of the ionization state of the active site aspartates

      JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    77. RODGERS JD; LAM PYS; JOHNSON BL; WANG HS; KO SS; SEITZ SP; TRAINOR GL; ANDERSON PS; KLABE RM; BACHELER LT; CORDOVA B; GARBER S; REID C; WRIGHT MR; CHANG CH; ERICKSONVIITANEN S
      DESIGN AND SELECTION OF DMP-850 AND DMP-851 - THE NEXT-GENERATION OF CYCLIC UREA HIV PROTEASE INHIBITORS

      Chemistry & biology
    78. PATEL M; KALTENBACH RF; NUGIEL DA; MCHUGH RJ; JADHAV PK; BACHELER LT; CORDOVA BC; KLABE RM; ERICKSONVIITANEN S; GARBER S; REID C; SEITZ SP
      THE SYNTHESIS OF SYMMETRICAL AND UNSYMMETRICAL P1 P1' CYCLIC UREAS ASHIV PROTEASE INHIBITORS/

      Bioorganic & medicinal chemistry letters
    79. PATEL M; BACHELER LT; RAYNER MM; CORDOVA BC; KLABE RM; ERICKSONVIITANEN S; SEITZ SP
      THE SYNTHESIS AND EVALUATION OF CYCLIC UREAS AS HIV PROTEASE INHIBITORS - MODIFICATIONS OF THE P1 P1' RESIDUES/

      Bioorganic & medicinal chemistry letters
    80. Chen, XQ; Kempf, DJ; Sham, HL; Green, BE; Molla, A; Korneyeva, M; Vasavanonda, S; Wideburg, NE; Saldivar, A; Marsh, KC; McDonald, E; Norbeck, DW
      Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P-3 ligands

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    81. Han, W; Pelletier, JC; Hodge, CN
      Tricyclic ureas: A new class of HIV-1 protease inhibitors

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    82. Ulysse, LG; Chmielewski, J
      Restricting the flexibility of crosslinked, interfacial peptide inhibitorsof HIV-1 protease

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    83. ZUTSHI R; SHULTZ MD; ULYSSE L; LUTGRING R; BISHOP P; SCHWEITZER B; VOGEL K; FRANCISKOVICH J; WILSON M; CHMIELEWSKI J
      INHIBITING THE DIMERIZATION OF HIV-1 PROTEASE

      Synlett
    84. OPREA TI; MARSHALL GR
      RECEPTOR-BASED PREDICTION OF BINDING AFFINITIES

      Perspectives in drug discovery and design
    85. HOLLOWAY MK
      A-PRIORI PREDICTION OF LIGAND AFFINITY BY ENERGY MINIMIZATION

      Perspectives in drug discovery and design
    86. MARTIN YC
      3D QSAR - CURRENT STATE, SCOPE, AND LIMITATIONS

      Perspectives in drug discovery and design
    87. NORINDER U
      RECENT PROGRESS IN COMFA METHODOLOGY AND RELATED TECHNIQUES

      Perspectives in drug discovery and design
    88. LIN JH; LU AYH
      INHIBITION AND INDUCTION OF CYTOCHROME-P450 AND THE CLINICAL IMPLICATIONS

      Clinical pharmacokinetics
    89. KEMPF DJ; RODE RA; XU Y; SUN E; HEATHCHIOZZI ME; VALDES J; JAPOUR AJ; DANNER S; BOUCHER C; MOLLA A; LEONARD JM
      THE DURATION OF VIRAL SUPPRESSION DURING PROTEASE INHIBITOR THERAPY FOR HIV-1 INFECTION IS PREDICTED BY PLASMA HIV-1 RNA AT THE NADIR

      AIDS
    90. MOLLA A; GRANNEMAN GR; SUN E; KEMPF DJ
      RECENT DEVELOPMENTS IN HIV PROTEASE INHIBITOR THERAPY

      Antiviral research
    91. RACE EM; ADELSONMITTY J; KRIEGEL GR; BARLAM TF; REIMANN KA; LETVIN NL; JAPOUR AJ
      FOCAL MYCOBACTERIAL LYMPHADENITIS FOLLOWING INITIATION OF PROTEASE-INHIBITOR THERAPY IN PATIENTS WITH ADVANCED HIV-1 DISEASE

      Lancet
    92. HSU A; GRANNEMAN GR; CAO GL; CAROTHERS L; JAPOUR A; ELSHOURBAGY T; DENNIS S; BERG J; ERDMAN K; LEONARD JM; SUN EG
      PHARMACOKINETIC INTERACTION BETWEEN RITONAVIR AND INDINAVIR IN HEALTHY-VOLUNTEERS

      Antimicrobial agents and chemotherapy
    93. LIARD F; JARAMILLO J; PARIS WL; YOAKIM C
      PHARMACOKINETIC ASPECTS OF PALINAVIR, AN HIV PROTEASE INHIBITOR, IN SPRAGUE-DAWLEY RATS

      Journal of pharmaceutical sciences
    94. WACHER VJ; SILVERMAN JA; ZHANG YC; BENET LZ
      ROLE OF P-GLYCOPROTEIN AND CYTOCHROME-P450 3A IN LIMITING ORAL ABSORPTION OF PEPTIDES AND PEPTIDOMIMETICS

      Journal of pharmaceutical sciences
    95. VONMOLTKE LL; GREENBLATT DJ; DUAN SX; DAILY JP; HARMATZ JS; SHADER RI
      INHIBITION OF DESIPRAMINE HYDROXYLATION (CYTOCHROME P450-2D6) IN-VITRO BY QUINIDINE AND BY VIRAL PROTEASE INHIBITORS - RELATION TO DRUG-INTERACTIONS IN-VIVO

      Journal of pharmaceutical sciences
    96. KEMPF DJ; SHAM HL; MARSH KC; FLENTGE CA; BETEBENNER D; GREEN BE; MCDONALD E; VASAVANONDA S; SALDIVAR A; WIDEBURG NE; KATI WM; RUIZ L; ZHAO C; FINO LM; PATTERSON J; MOLLA A; PLATTNER JJ; NORBECK DW
      DISCOVERY OF RITONAVIR, A POTENT INHIBITOR OF HIV PROTEASE WITH HIGH ORAL BIOAVAILABILITY AND CLINICAL EFFICACY

      Journal of medicinal chemistry
    97. TURNER SR; STROHBACH JW; TOMMASI RA; ARISTOFF PA; JOHNSON PD; SKULNICK HI; DOLAK LA; SEEST EP; TOMICH PK; BOHANAN MJ; HORNG MM; LYNN JC; CHONG KT; HINSHAW RR; WATENPAUGH KD; JANAKIRAMAN MN; THAISRIVONGS S
      TIPRANAVIR (PNU-140690) - A POTENT, ORALLY BIOAVAILABLE NONPEPTIDIC HIV PROTEASE INHIBITOR OF THE 5,6-DIHYDRO-4-HYDROXY-2-PYRONE SULFONAMIDE CLASS

      Journal of medicinal chemistry
    98. DELUCCA GV; KIM UT; LIANG J; CORDOVA B; KLABE RM; GARBER S; BACHELER LT; LAM GN; WRIGHT MR; LOGUE KA; ERICKSONVIITANEN S; KO SS; TRAINOR GL
      NONSYMMETRIC P2 P2' CYCLIC UREA HIV PROTEASE INHIBITORS - STRUCTURE-ACTIVITY RELATIONSHIP, BIOAVAILABILITY, AND RESISTANCE PROFILE OF MONOINDAZOLE-SUBSTITUTED P2 ANALOGS/

      Journal of medicinal chemistry
    99. HAN Q; CHANG CH; LI RH; RU Y; JADHAV PK; LAM PYS
      CYCLIC HIV PROTEASE INHIBITORS - DESIGN AND SYNTHESIS OF ORALLY BIOAVAILABLE, PYRAZOLE P2 P2' CYCLIC UREAS WITH IMPROVED POTENCY/

      Journal of medicinal chemistry
    100. ALA PJ; DELOSKEY RJ; HUSTON EE; JADHAV PK; LAM PYS; EYERMANN CJ; HODGE CN; SCHADT MC; LEWANDOWSKI FA; WEBER PC; MCCABE DD; DUKE JL; CHANG CH
      MOLECULAR RECOGNITION OF CYCLIC UREA HIV-1 PROTEASE INHIBITORS

      The Journal of biological chemistry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/02/20 alle ore 22:29:28